Search results for "Sms"

showing 10 items of 10610 documents

Gut microbiota and cancer: How gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy

2019

Gut microbiota is involved in gastrointestinal carcinogenesis. Also, it modulates the activity, efficacy and toxicity of several chemotherapy agents, such as gemcitabine, cyclophosphamide, irinotecan, cisplatin and 5-Fluorouracil, and target therapy, such as tyrosine kinase inhibitors. More recently, accumulating data suggest that the composition of gut microbiota may also affect efficacy and toxicity of cancer immunotherapy. Therefore, the manipulation of gut microbiota through antibiotics, probiotics, prebiotics or fecal transplantation has been investigating with the aim to improve efficacy and mitigate toxicity of anticancer drugs.

0301 basic medicineSettore MED/06 - Oncologia Medicamedicine.drug_class5-Fluorouracilmedicine.medical_treatmentAntibioticsAntineoplastic AgentsImmune checkpoint inhibitorGut floraPharmacologyIrinotecandigestive systemImmune checkpoint inhibitors03 medical and health sciences0302 clinical medicineCancer immunotherapyNeoplasmsmedicineAnimalsHumansCyclophosphamide5-Fluorouracil; Cisplatin; Cyclophosphamide; Gemcitabine; Immune checkpoint inhibitors; Irinotecan; Microbiota; Tyrosine kinase inhibitorsTyrosine kinase inhibitorsChemotherapybiologybusiness.industryMicrobiotaCancerHematologyFecal Microbiota Transplantationbiology.organism_classificationmedicine.diseaseGemcitabineGemcitabineGastrointestinal MicrobiomeIrinotecan030104 developmental biologyOncology030220 oncology & carcinogenesisToxicityImmunotherapyCisplatinbusinessmedicine.drugCritical Reviews in Oncology/Hematology
researchProduct

Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential

2018

Abstract: Introduction: Pancreatic neuroendocrine tumors (pNETs) represent a small part of pancreatic neoplasms, and the knowledge about their indolent clinical course remains a subject of investigation. They occur sporadically or as part of familial cancer syndromes and are classified by WHO in 3 categories. There is ongoing research to understand their molecular profiling and leading mutations.Areas covered: The aim of this review is to clarify the overall aspects of tumorigenesis, to expose the latest developments in understanding the course of the disease and the possible therapeutic implications of these. The review also discusses functional and non-functional pNETs and associated inhe…

0301 basic medicineSettore MED/06 - Oncologia Medicamedicine.medical_treatmentClinical Decision-MakingAntineoplastic AgentsDiseaseNeuroendocrine tumorsBioinformaticsTargeted therapy03 medical and health sciences0302 clinical medicinePredictive Value of TestsFunctional tumorBiomarkers TumormedicineHumansProfiling (information science)Molecular Targeted Therapyneurondocrine tumorPrecision MedicineTherapeutic strategymolecular pathwayHepatologybusiness.industryGene Expression ProfilingGastroenterologyClinical coursehereditary syndrometargeted therapymedicine.diseaseGene Expression Regulation NeoplasticPancreatic NeoplasmsNeuroendocrine Tumors030104 developmental biology030220 oncology & carcinogenesispancreatic tumorFamilial CancerHuman medicinebusinessSignal TransductionExpert review of gastroenterology & hepatology
researchProduct

Helicobacter pylori and Epstein–Barr Virus Infection in Gastric Diseases: Correlation with IL-10 and IL1RN Polymorphism

2019

Introduction. Helicobacter pylori and Epstein–Barr virus (EBV) infection have recently been shown to be associated with gastric diseases. Polymorphisms in genes encoding cytokines such as interleukin 10 (IL-10) and interleukin 1 Receptor (IL-1RN) influence cytokine secretion levels and appear to contribute to the risk of developing gastroduodenal diseases. To our knowledge, this is the first preliminary study to address the association of coinfection with H. pylori and EBV and their correlation with genetic predisposition in the development of gastric diseases. Methods. Gastric biopsy samples of 96 patients with different gastric diseases were used. Results. Our results showed that the rate…

0301 basic medicineSettore MED/07 - Microbiologia E Microbiologia ClinicaArticle Subjectpolymorphism gastric cancer IL-10Chronic gastritislcsh:RC254-28203 medical and health sciences0302 clinical medicineEBVHelicobactermedicineCagAEpstein–Barr virus infectionbiologybusiness.industryMALT lymphomaHelicobacter pylorimedicine.diseasebiology.organism_classificationlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensdigestive system diseases030104 developmental biologyOncology030220 oncology & carcinogenesisImmunologyCoinfectionCytokine secretionGastritismedicine.symptombusinessResearch ArticleJournal of Oncology
researchProduct

Potential Uses of Olive Oil Secoiridoids for the Prevention and Treatment of Cancer: A Narrative Review of Preclinical Studies

2021

The Mediterranean diet (MD) is a combination of foods mainly rich in antioxidants and anti-inflammatory nutrients that have been shown to have many health-enhancing effects. Extra-virgin olive oil (EVOO) is an important component of the MD. The importance of EVOO can be attributed to phenolic compounds, represented by phenolic alcohols, hydroxytyrosol, and tyrosol, and to secoiridoids, which include oleocanthal, oleacein, oleuropein, and ligstroside (along with the aglycone and glycosidic derivatives of the latter two). Each secoiridoid has been studied and characterized, and their effects on human health have been documented by several studies. Secoiridoids have antioxidant, anti-inflammat…

0301 basic medicineSettore MED/09 - Medicina InternaSettore CHIM/10 - Chimica Degli AlimentiMediterranean dietAnti-Inflammatory AgentsReviewDiet MediterraneanAntioxidantsCyclopentane Monoterpeneslcsh:Chemistrychemistry.chemical_compound0302 clinical medicineGlucosidesNeoplasmsIridoidslcsh:QH301-705.5SpectroscopyTraditional medicineGeneral MedicinePhenylethyl AlcoholComputer Science Applications030220 oncology & carcinogenesissecoiridoidsIridoid GlucosidesAntineoplastic AgentsoleocanthalCatalysisInorganic Chemistry03 medical and health sciencesPhenolsOleuropeinOleocanthalmedicineAnimalsHumanscanceroleaceinPhysical and Theoretical ChemistryOlive OilMolecular BiologyPyransAldehydesOrganic ChemistryCancermedicine.diseaseTyrosol030104 developmental biologyAglyconelcsh:Biology (General)lcsh:QD1-999chemistryoleuropeinligstrosideHydroxytyrosolOlive oilInternational Journal of Molecular Sciences
researchProduct

Trichomonicidal and parasite membrane damaging activity of bidesmosic saponins from Manilkara rufula.

2017

The infection caused by Trichomonas vaginalis is the most common but overlooked non-viral sexually transmitted disease worldwide. Treatment relies on one class of drugs, the 5-nitroimidazoles, but resistance is widespread. New drugs are urgently needed. We reported the effect of crude and purified saponin fractions of Manilkara rufula against Trichomonas vaginalis. The compound responsible for antitrichomonal activity was isolated and identified as an uncommon bidesmosic saponin, Mi-saponin C. This saponin eliminated parasite viability without toxicity against the human vaginal epithelial line (HMVII). In addition, the isolated saponin fraction improved the metronidazole effect against a me…

0301 basic medicineSexually transmitted diseaseNeutrophilsCell MembranesSaponinlcsh:Medicinemedicine.disease_causePathology and Laboratory MedicineBiochemistryMass SpectrometryAnalytical ChemistryWhite Blood CellsOxidative DamageSpectrum Analysis TechniquesAnimal CellsMedicine and Health SciencesParasite hostingElectron Microscopylcsh:Sciencechemistry.chemical_classificationSexually transmitted diseasesTrichomonas VaginalisMicroscopyMultidisciplinaryEukaryotaProtistsMatrix-Assisted Laser Desorption Ionization Mass Spectrometrymusculoskeletal systemChemistryFlagellaToxicityPhysical SciencesVaginaTrichomonasFemaleCellular TypesCellular Structures and OrganellesPathogensMalalties de transmissió sexualIntracellularmedicine.drugResearch ArticlePathogen MotilityEfecte dels medicaments sobre els microorganismesVirulence FactorsImmune CellsImmunologyBiologyResearch and Analysis Methodscomplex mixturesMicrobiologyCell Line03 medical and health sciencesParasite Groupsparasitic diseasesmedicineTrichomonas vaginalisSaponinasHumansTrophozoitesResistència als medicamentsManilkaraBlood CellsCell Membranelcsh:ROrganismsBiology and Life SciencesCell BiologyIntracellular MembranesSaponinsbiology.organism_classificationCell membranescarbohydrates (lipids)MetronidazoleMicroscopy Electron030104 developmental biologychemistryManilkara rufulaDrug resistanceEffect of drugs on microorganismsTrichomonas vaginalisParasitologyTransmission Electron Microscopylcsh:QReactive Oxygen SpeciesApicomplexaMembranes cel·lularsChromatography LiquidPRODUTOS NATURAISPLoS ONE
researchProduct

Microorganism adhesion using silicon dioxide: An experimental study

2020

In this study, spectrophotometry was used to measure changes in the absorbance properties of yeast, Gram-positive, and Gram-negative bacteria after their attachment to silicon dioxide microparticles (silica). The goal of this study was to determine whether spectrophotometry is an effective method to distinguish these microorganisms from one another and determine whether they have an affinity for silicon dioxide. The experiments were performed by examining the light absorption properties of yeast, Gram-positive and Gram-negative bacteria in a spectrophotometer, both with and without silicon dioxide microparticles. The experiments produced a number of promising results. First, the spectrophot…

0301 basic medicineSilicon dioxideMicroorganismMicroorganismsMicrobiologyBiochemistryArticleClinical researchAbsorbance03 medical and health scienceschemistry.chemical_compound0302 clinical medicineSpectrophotometrySilicon dioxidemedicinelcsh:Social sciences (General)Bacterial typeslcsh:Science (General)Infectious diseaseMultidisciplinaryChromatographyBacteriamedicine.diagnostic_testbiologyChemistryNear-infrared spectroscopyLaboratory medicinebiology.organism_classificationYeastYeast030104 developmental biologySpectrophotometrylcsh:H1-99030217 neurology & neurosurgeryBacterialcsh:Q1-390Heliyon
researchProduct

Solid nanoemulsion as antigen and immunopotentiator carrier for transcutaneous immunization

2015

Imiquimod, a toll-like receptor 7 (TLR7) agonist, is an active pharmaceutical ingredient (API) established for the topical treatment of several dermal cancerous and precancerous skin lesions. Within this work, the immunostimulatory effect of imiquimod is further exploited in a transcutaneous immunization (TCI) approach based on a solid nanoemulsion (SN) formulation. SN contains a combination of imiquimod with the model peptide antigen SIINFEKL as a novel approach to omit needle and syringe and optimize dermal antigen administration. Excipients including sucrose fatty acid esters and the pharmaceutically acceptable oils MCT (middle chain triglycerides), avocado oil, jojoba wax and squalene a…

0301 basic medicineSkin NeoplasmsChemistry PharmaceuticalImmunologyAntineoplastic AgentsImiquimodImmunopotentiatorBiologyAdministration Cutaneous030226 pharmacology & pharmacyMice03 medical and health sciencesFreeze-dryingSqualenechemistry.chemical_compoundDrug Delivery Systems0302 clinical medicineAdjuvants ImmunologicAntigenIn vivomedicineAnimalsHumansActive ingredientImiquimodChromatographyVaccinationPermeationNanostructuresMice Inbred C57BL030104 developmental biologychemistryLangerhans CellsImmunologyAminoquinolinesImmunizationOilsPrecancerous Conditionsmedicine.drugCellular Immunology
researchProduct

Strategies in DNA vaccine for melanoma cancer

2020

According to reports of the international agency for cancer on research, although malignant melanoma shows less prevalence than nonmelanoma skin cancers, it is the major cause of skin cancer mortality. Given that, the production of effective vaccines to control melanoma is eminently required. In this regard, DNA-based vaccines have been extensively investigated for melanoma therapy. DNA vaccines are capable of inducing both cellular and humoral branches of immune responses. These vaccines possess some valuable advantages such as lack of severe side effects and high stability compared to conventional vaccination methods. The ongoing studies are focused on novel strategies in the development …

0301 basic medicineSkin NeoplasmsDermatologyCancer VaccinesGeneral Biochemistry Genetics and Molecular BiologyDNA vaccination03 medical and health sciences0302 clinical medicineImmune systemVaccines DNAmedicineHumansMelanomaMelanoma-associated antigenbusiness.industryMelanomaCancermedicine.diseaseVaccinationClinical trial030104 developmental biologyOncology030220 oncology & carcinogenesisImmunologySkin cancerbusinessPigment Cell & Melanoma Research
researchProduct

Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma

2016

CTLA-4 and PD-1 are potential targets for tumor-induced downregulation of lymphocytic immune responses. Immune checkpoint-modifying monoclonal antibodies oppose these effects, inducing T cell-mediated immune responses to various tumors including melanoma. Both anti-CTLA-4 and anti-PD-1 antibodies modify the interaction between tumor, antigen-presenting cells, and T lymphocytes. With respect to overall survival, clinical studies have shown a major benefit for the anti-CTLA-4 antibody ipilimumab as well as the two anti-PD-1 antibodies nivolumab and pembrolizumab. Following approval of ipilimumab in 2011, the latter two achieved market authorization in the summer of 2015. Immune responses thus…

0301 basic medicineSkin NeoplasmsDrug-Related Side Effects and Adverse Reactionsmedicine.drug_classMedizinAntineoplastic AgentsIpilimumabDermatologyPembrolizumabMonoclonal antibody03 medical and health sciences0302 clinical medicineImmune systemmedicineHumansCTLA-4 AntigenMelanomabiologybusiness.industryMelanomaAntibodies Monoclonalmedicine.diseaseIpilimumabImmune checkpoint030104 developmental biology030220 oncology & carcinogenesisImmunologybiology.proteinNivolumabAntibodybusinessmedicine.drugJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct

Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization.

2017

Abstract Background The epidermal application of the Toll Like Receptor 7 agonist imiquimod and a T-cell peptide epitope (transcutaneous immunization, TCI) mediates systemic peptide-specific cytotoxic T-cell (CTL) responses and leads to tumor protection in a prophylactic tumor setting. However, it does not accomplish memory formation or permanent defiance of tumors in a therapeutic set-up. As a distinct immunologic approach, CTLA-4 blockade augments systemic immune responses and has shown long-lasting effects in preclinical experiments as well as in clinical trials. Objective The study investigates the vaccination capacity of TCI in combination with the checkpoint inhibitor CTLA-4 in matter…

0301 basic medicineSkin NeoplasmsOvalbuminmedicine.medical_treatmentMelanoma Experimentalchemical and pharmacologic phenomenaDermatologyBiochemistryT-Lymphocytes RegulatoryEpitope03 medical and health sciencesMice0302 clinical medicineImmune systemAntineoplastic Agents ImmunologicalAdjuvants ImmunologicmedicineCytotoxic T cellAnimalsHumansCTLA-4 AntigenMolecular BiologyImiquimodMembrane Glycoproteinsbusiness.industryMelanomahemic and immune systemsDrug SynergismTLR7Immunotherapymedicine.diseaseFlow CytometryXenograft Model Antitumor AssaysPeptide FragmentsMice Inbred C57BLCTL*030104 developmental biologyToll-Like Receptor 7CTLA-4030220 oncology & carcinogenesisImmunologyAminoquinolinesImmunotherapybusinessImmunologic MemoryT-Lymphocytes CytotoxicJournal of dermatological science
researchProduct